These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24357520)

  • 1. The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b.
    Li JY; Walker LD; Tyagi AM; Adams J; Weitzmann MN; Pacifici R
    J Bone Miner Res; 2014 Jan; 29(1):43-54. PubMed ID: 24357520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
    Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell-expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment.
    Robinson JW; Li JY; Walker LD; Tyagi AM; Reott MA; Yu M; Adams J; Weitzmann MN; Pacifici R
    J Bone Miner Res; 2015 Apr; 30(4):695-705. PubMed ID: 25359628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH.
    Bedi B; Li JY; Tawfeek H; Baek KH; Adams J; Vangara SS; Chang MK; Kneissel M; Weitzmann MN; Pacifici R
    Proc Natl Acad Sci U S A; 2012 Mar; 109(12):E725-33. PubMed ID: 22393015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling.
    Terauchi M; Li JY; Bedi B; Baek KH; Tawfeek H; Galley S; Gilbert L; Nanes MS; Zayzafoon M; Guldberg R; Lamar DL; Singer MA; Lane TF; Kronenberg HM; Weitzmann MN; Pacifici R
    Cell Metab; 2009 Sep; 10(3):229-40. PubMed ID: 19723499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.
    D'Amelio P; Sassi F; Buondonno I; Fornelli G; Spertino E; D'Amico L; Marchetti M; Lucchiari M; Roato I; Isaia GC
    Osteoporos Int; 2015 Dec; 26(12):2785-91. PubMed ID: 26068297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status.
    Ross RD; Mashiatulla M; Robling AG; Miller LM; Sumner DR
    Calcif Tissue Int; 2016 Feb; 98(2):149-57. PubMed ID: 26514840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
    Sun W; Shi Y; Lee WC; Lee SY; Long F
    Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
    Wu J; Cai XH; Qin XX; Liu YX
    Z Gerontol Geriatr; 2018 Jul; 51(5):550-556. PubMed ID: 28364259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading.
    Morse A; Schindeler A; McDonald MM; Kneissel M; Kramer I; Little DG
    J Bone Miner Res; 2018 Mar; 33(3):486-498. PubMed ID: 29090474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
    Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
    J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
    Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
    Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
    Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
    Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.
    Chandra A; Lin T; Young T; Tong W; Ma X; Tseng WJ; Kramer I; Kneissel M; Levine MA; Zhang Y; Cengel K; Liu XS; Qin L
    J Bone Miner Res; 2017 Feb; 32(2):360-372. PubMed ID: 27635523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin.
    Roser-Page S; Vikulina T; Weiss D; Habib MM; Beck GR; Pacifici R; Lane TF; Weitzmann MN
    Ann N Y Acad Sci; 2018 Mar; 1415(1):21-33. PubMed ID: 29500936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTH expands short-term murine hemopoietic stem cells through T cells.
    Li JY; Adams J; Calvi LM; Lane TF; DiPaolo R; Weitzmann MN; Pacifici R
    Blood; 2012 Nov; 120(22):4352-62. PubMed ID: 22955916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists.
    Holdsworth G; Greenslade K; Jose J; Stencel Z; Kirby H; Moore A; Ke HZ; Robinson MK
    Bone; 2018 Feb; 107():93-103. PubMed ID: 29129759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.
    Tsourdi E; Lademann F; Ominsky MS; Rijntjes E; Köhrle J; Misof BM; Roschger P; Klaushofer K; Hofbauer LC; Rauner M
    Endocrinology; 2017 Nov; 158(11):3765-3777. PubMed ID: 28973221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone.
    Pacifici R
    Ann N Y Acad Sci; 2016 Jan; 1364(1):11-24. PubMed ID: 26662934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.